Jan 05, 2024 Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Jan 04, 2024 Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
Jan 02, 2024 Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Nov 13, 2023 Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Sep 05, 2023 Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 10, 2023 Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights